Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation
Uloženo v:
| Název: | Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation |
|---|---|
| Autoři: | Martina Aguiar Bucsai, Christian Idel, Barbara Wollenberg, Christine Mannhalter, Admar Verschoor |
| Zdroj: | Platelets, Vol 33, Iss 8, Pp 1192-1198 (2022) |
| Informace o vydavateli: | Informa UK Limited, 2022. |
| Rok vydání: | 2022 |
| Témata: | Blood Platelets, tirofiban, Platelet Aggregation, Platelet Glycoprotein GPIIb-IIIa Complex, Platelet Activation, platelet inhibition, P-Selectin, 03 medical and health sciences, 0302 clinical medicine, Tirofiban, platelet aggregation, 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid, platelet activation, Humans, Tyrosine, Diseases of the blood and blood-forming organs, Receptors, Thrombin, RC633-647.5, Chemokine CCL5, platelet degranulation, Platelet Aggregation Inhibitors |
| Popis: | We aimed to investigate the effects of integrin αIIbβ3 inhibitor tirofiban on hallmarks of platelet activation, degranulation, and aggregation during its use to analyze activated but non-complexed platelets via flow cytometry. To do so, we used washed platelets from healthy human donors. We combined aggregometry, an assay of platelet functionality, with flow cytometry and ELISA to detect and correlate, respectively, platelet aggregation, activation, and granule release. While tirofiban effectively inhibited agonist-induced platelet aggregation (thrombin receptor-activating peptide 6 (TRAP), convulxin (CVX), U46619 and IV.3), the surface expression of P-selectin and CD63 and granule release of RANTES were significantly increased, indicating that tirofiban enhances degranulation, uncoupled from aggregation. The results show that tirofiban alters the activation phenotype of platelets, something that should be considered when using tirofiban to enable flow cytometric analysis of activated but unaggregated platelet suspensions. |
| Druh dokumentu: | Article Other literature type |
| Jazyk: | English |
| ISSN: | 1369-1635 0953-7104 |
| DOI: | 10.1080/09537104.2022.2078489 |
| DOI: | 10.6084/m9.figshare.20070108 |
| DOI: | 10.6084/m9.figshare.20070108.v1 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/35701857 https://doaj.org/article/67d154783c2d4217a594f18f8ee8fe79 |
| Rights: | CC BY |
| Přístupové číslo: | edsair.doi.dedup.....9e80b286893e1f4297f2433fe55838fe |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | We aimed to investigate the effects of integrin αIIbβ3 inhibitor tirofiban on hallmarks of platelet activation, degranulation, and aggregation during its use to analyze activated but non-complexed platelets via flow cytometry. To do so, we used washed platelets from healthy human donors. We combined aggregometry, an assay of platelet functionality, with flow cytometry and ELISA to detect and correlate, respectively, platelet aggregation, activation, and granule release. While tirofiban effectively inhibited agonist-induced platelet aggregation (thrombin receptor-activating peptide 6 (TRAP), convulxin (CVX), U46619 and IV.3), the surface expression of P-selectin and CD63 and granule release of RANTES were significantly increased, indicating that tirofiban enhances degranulation, uncoupled from aggregation. The results show that tirofiban alters the activation phenotype of platelets, something that should be considered when using tirofiban to enable flow cytometric analysis of activated but unaggregated platelet suspensions. |
|---|---|
| ISSN: | 13691635 09537104 |
| DOI: | 10.1080/09537104.2022.2078489 |